Spero Therapeutics (SPRO) Profit After Tax (2016 - 2026)

Spero Therapeutics (SPRO) has 11 years of Profit After Tax data on file, last reported at -$7.2 million in Q1 2026.

• Quarterly Profit After Tax rose 48.2% year-over-year to -$7.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.2 million (up 121.85% YoY) and the FY2025 annual result came in at $8.6 million, up 112.54% from the prior year.
• Profit After Tax declined to -$7.2 million in Q1 2026, from $31.5 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $51.2 million in Q4 2023 to a low of -$32.8 million in Q1 2022.
• A 5-year average of -$5.3 million and a median of -$11.9 million in 2023 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2024 — Profit After Tax sank 433.54% — and 2025, when it surged 251.03%.
• Tracing SPRO's Profit After Tax over 5 years: stood at $26.8 million in 2022, then surged by 91.18% to $51.2 million in 2023, then sank by 140.79% to -$20.9 million in 2024, then surged by 251.03% to $31.5 million in 2025, then sank by 122.82% to -$7.2 million in 2026.
• The last three Profit After Tax figures came in at -$7.2 million (Q1 2026), $31.5 million (Q4 2025), and -$7.4 million (Q3 2025), per Business Quant data.